Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double […]
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the […]
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.